ATE491475T1 - Konjugate enthaltend gm-csf und ein polymer - Google Patents

Konjugate enthaltend gm-csf und ein polymer

Info

Publication number
ATE491475T1
ATE491475T1 AT05771041T AT05771041T ATE491475T1 AT E491475 T1 ATE491475 T1 AT E491475T1 AT 05771041 T AT05771041 T AT 05771041T AT 05771041 T AT05771041 T AT 05771041T AT E491475 T1 ATE491475 T1 AT E491475T1
Authority
AT
Austria
Prior art keywords
conjugates
csf
polymer
conjugates containing
methods
Prior art date
Application number
AT05771041T
Other languages
English (en)
Inventor
Mary Bossard
Ping Zhang
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Application granted granted Critical
Publication of ATE491475T1 publication Critical patent/ATE491475T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
AT05771041T 2004-07-16 2005-07-14 Konjugate enthaltend gm-csf und ein polymer ATE491475T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58860104P 2004-07-16 2004-07-16
PCT/US2005/025052 WO2006019950A2 (en) 2004-07-16 2005-07-14 Conjugates of a gm-csf moiety and a polymer

Publications (1)

Publication Number Publication Date
ATE491475T1 true ATE491475T1 (de) 2011-01-15

Family

ID=35565892

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05771041T ATE491475T1 (de) 2004-07-16 2005-07-14 Konjugate enthaltend gm-csf und ein polymer

Country Status (12)

Country Link
US (2) US20060036080A1 (de)
EP (1) EP1768700B1 (de)
JP (1) JP2008506704A (de)
KR (1) KR101330338B1 (de)
CN (1) CN101031323A (de)
AT (1) ATE491475T1 (de)
AU (1) AU2005275108B2 (de)
CA (1) CA2573262C (de)
DE (1) DE602005025355D1 (de)
ES (1) ES2355642T3 (de)
MX (1) MX2007000568A (de)
WO (1) WO2006019950A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007009208A1 (en) * 2005-06-02 2007-01-25 Cangene Corporation Poly(ethylene glocol) modified human gm-csf with increased biological activity
CU23556A1 (es) * 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
EP1986695B1 (de) * 2006-02-21 2015-06-03 Nektar Therapeutics Segmentierte abbaubare polymere und daraus hergestellte konjugate
EP1834963A1 (de) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-Polymer-Konjugate von Proteinen und Verfahren zur deren Erstellung
SI2054074T1 (sl) 2006-08-04 2014-12-31 Prolong Pharmaceuticals Llc Modificiran eritropoetin
ITMI20061624A1 (it) * 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
JP2008069073A (ja) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd ラクトフェリン複合体及びその製造方法
CA2723821C (en) * 2008-05-16 2017-05-02 Nektar Therapeutics Conjugates of a cholinesterase moiety and a polymer
US20110165113A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of v681-like peptides
AU2009292643B2 (en) 2008-09-19 2016-02-18 Nektar Therapeutics Polymer conjugates of therapeutic peptides
WO2010033221A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of protegrin peptides
TW201808987A (zh) 2016-06-08 2018-03-16 健生生物科技公司 Ｇｍ－ｃｓｆ變體及使用方法
KR101947342B1 (ko) * 2017-05-05 2019-02-12 주식회사 유비프로틴 Gm-csf 반감기를 증가시키는 방법
CA3201327A1 (en) * 2020-12-08 2022-06-16 Partner Therapeutics, Inc. Manufacture of granulocyte macrophage-colony stimulating factor

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908763A (en) * 1984-07-06 1999-06-01 Novartis Corporation DNA encoding GM-CSF and a method of producing GM-CSF protein
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
JP2958019B2 (ja) * 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US5214131A (en) * 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
ES2085297T3 (es) * 1989-05-27 1996-06-01 Sumitomo Pharma Procedimiento para preparar derivados de poli(etilenglicol) y proteina modificada.
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
JPH05506673A (ja) * 1991-02-22 1993-09-30 アムジエン・インコーポレーテツド 迅速な創傷の治癒を促進するためのｇｍ―ｃｓｆ及びｇ―ｃｓｆの使用
GB9317618D0 (en) * 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5766581A (en) * 1994-03-31 1998-06-16 Amgen Inc. Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation
US5629384A (en) * 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
AU5773798A (en) * 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
US6548644B1 (en) * 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
IL133974A0 (en) * 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US6221378B1 (en) * 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
CN1318443C (zh) * 2000-05-16 2007-05-30 博尔德生物技术公司 含游离半胱氨酸残基的蛋白重折叠的方法
WO2002002132A1 (en) * 2000-06-30 2002-01-10 Smithkline Beecham Corporation Chemokine conjugates
AU2000202A (en) * 2000-10-31 2002-05-15 Pr Pharmaceuticals Inc Methods and compositions for enhanced delivery of bioactive molecules
US20020142964A1 (en) * 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
EP1446438A2 (de) * 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Verzweigte polymere und ihre konjugate
WO2004012773A1 (en) 2002-07-24 2004-02-12 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
BR0313650A (pt) * 2002-08-20 2007-08-14 Genitrix Llc composição, vetor de expressão, composição de vacina e uso
MXPA05002620A (es) * 2002-09-09 2005-05-05 Nektar Therapeutics Al Corp Alcanales polimericos solubles en agua.
PL396711A1 (pl) * 2002-12-26 2011-12-19 Mountain View Pharmaceuticals, Inc. Koniugaty polimerów z cytokinami, chemokinami, czynnikami wzrostu, hormonami polipeptydowymi i ich antagonistami, kompozycja farmaceutyczna i sposób zapobiegania, diagnozowania lub leczenia
US7208145B2 (en) * 2002-12-31 2007-04-24 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a ketone or a related functional group
US7887789B2 (en) * 2003-05-23 2011-02-15 Nektar Therapeutics Polymer derivatives having particular atom arrangements

Also Published As

Publication number Publication date
CA2573262A1 (en) 2006-02-23
MX2007000568A (es) 2007-03-30
CN101031323A (zh) 2007-09-05
EP1768700A2 (de) 2007-04-04
KR20070043852A (ko) 2007-04-25
US20140044672A1 (en) 2014-02-13
EP1768700B1 (de) 2010-12-15
AU2005275108A1 (en) 2006-02-23
US20060036080A1 (en) 2006-02-16
JP2008506704A (ja) 2008-03-06
AU2005275108B2 (en) 2011-05-12
DE602005025355D1 (de) 2011-01-27
WO2006019950A3 (en) 2006-08-03
WO2006019950A2 (en) 2006-02-23
CA2573262C (en) 2015-02-10
KR101330338B1 (ko) 2013-11-15
ES2355642T3 (es) 2011-03-29

Similar Documents

Publication Publication Date Title
MX2008001706A (es) Conjugados de una porcion g-csf y un polimero.
WO2004075923A3 (en) Polymer-factor viii moiety conjugates
WO2006005058A3 (en) Polymer-factor ix moiety conjugates
MXPA05003394A (es) Conjugados de polimero con antigenicidad disminuida, metodos de preparacion y usos de estos.
ATE491475T1 (de) Konjugate enthaltend gm-csf und ein polymer
HRP20050319A2 (en) Water-soluble polymer alkanals
EA202092025A1 (ru) Конъюгаты компонента il-2 и полимера
SE0401971D0 (sv) Piperidne derivatives
WO2006138572A3 (en) Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
BRPI0409133A (pt) formulações farmacêuticas contendo metilnaltrexona
WO2006110776A3 (en) Polyethylene glycol cojugates of antimicrobial agents
WO2006047419A3 (en) Heterobifunctional poly(ethylene glycol) and uses thereof
NZ600039A (en) Biocompatible biodegradable fumagillin analog conjugates
WO2007100902A3 (en) Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
WO2007127440A3 (en) Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
SE0401970D0 (sv) Novel compounds
WO2006138463A3 (en) Polymer-based compositions and conjugates of non-steroidal anti-inflammatory drugs
WO2005089805A3 (en) Polymer-based compositions and conjugates of hiv entry inhibitors
WO2009139905A3 (en) Conjugates of a cholinesterase moiety and a polymer
WO2006066020A3 (en) Releasable polymeric conjugates based on aliphatic biodegradable linkers
GB2436996B8 (en) Rigid amines
WO2010080720A3 (en) Conjugates of a lysosomal enzyme moiety and a water soluble polymer
WO2007117685A3 (en) Conjugates of an anti-tnf-alpha antibody
WO2006102659A3 (en) CONJUGATES OF AN hGH MOIETY AND A POLYMER
WO2006089228A3 (en) Conjugates of an epo moiety and a polymer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties